PER — Percheron Therapeutics Balance Sheet
0.000.00%
- AU$9.79m
- -AU$0.36m
- AU$0.37m
Annual balance sheet for Percheron Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 6.02 | 19.2 | 11 | 11.9 | 10.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.601 | 1.84 | 1.66 | 2.57 | 1.58 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6.7 | 22.2 | 12.7 | 14.5 | 12.4 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.302 | 0.217 | 0.151 | 0.057 | 0.035 |
Total Assets | 7 | 22.4 | 12.8 | 14.5 | 12.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.05 | 1.16 | 2.81 | 5.15 | 2.43 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.27 | 1.3 | 2.87 | 5.17 | 2.43 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 5.73 | 21.1 | 9.98 | 9.36 | 10 |
Total Liabilities & Shareholders' Equity | 7 | 22.4 | 12.8 | 14.5 | 12.4 |
Total Common Shares Outstanding |